SCENARIA View Phase 5.0

The FUJIFILM SCENARIA View Phase 5.0 is an advanced 128-slice computed tomography X-ray system designed for whole-body axial imaging, interventional needle guidance, and low-dose lung cancer screening. Its scientific methodology incorporates AI-driven features like AutoPose, enhanced motion-corrected reconstruction, and increased patient capacity, validated through rigorous testing to demonstrate performance equivalence and clinical utility.

FUJIFILM Corporation has obtained assessment for its SCENARIA View Phase 5.0, a computed tomography (CT) X-ray system, confirming its substantial equivalence to the previously marketed SCENARIA View 4.2. This regulatory approval enables the system's marketing for diverse clinical applications, including the acquisition of whole-body axial volumes, guidance for interventional needle procedures, and its utility as a low-dose CT option for lung cancer screening. The SCENARIA View Phase 5.0 is a 128-slice multi-slice CT system, integrating a gantry, operator workstation, patient table, and X-ray components. Key enhancements over its predicate device include the introduction of AutoPose, an AI-driven function for automatic scan and image reconstruction range setting, and RemoteRecon, which facilitates external PC-based reconstruction parameter control. Further modifications encompass an increased patient table capacity to 300kg, broader applicability of motion-corrected reconstruction for chest examinations, and expanded AutoPositioning support across various body regions. Non-clinical and clinical studies validated the system's performance, safety, and equivalence, affirming its consistent design, core technology, indications, and overall safety and efficacy with the predicate device.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI-based AutoPose function specifically improve workflow efficiency and diagnostic accuracy compared to manual methods in clinical settings?; What are the quantitative benefits of the increased patient table load capacity and expanded AutoPositioning support in terms of patient accessibility and scan versatility?; Can the document provide more detail on the specific types of motion artifacts addressed by the expanded motion-corrected reconstruction, especially for challenging chest examinations?; What are the detailed performance metrics (e.g., image resolution, contrast-to-noise ratio, radiation dose reduction) demonstrated in the non-clinical and clinical tests that support its equivalence and superiority in specific applications?; Beyond lung cancer screening, what other low-dose applications or future developments are envisioned for the SCENARIA View Phase 5.0 system?